Online inquiry

IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14587MR)

This product GTTS-WQ14587MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD38 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001775.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 952
UniProt ID P28907
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14587MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1800MR IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ADCT-402
GTTS-WQ9052MR IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IMC-18F1
GTTS-WQ1120MR IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-927
GTTS-WQ4560MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-936564
GTTS-WQ2783MR IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG-282
GTTS-WQ14027MR IVTScrip™ mRNA-Anti-LAG3, aLAG367(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA aLAG367
GTTS-WQ13599MR IVTScrip™ mRNA-Anti-APP, R1450(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA R1450
GTTS-WQ7510MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GC-1102
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW